Research programme: tumour maintenance gene antagonists - AVEO/Merck
Latest Information Update: 13 Aug 2007
Price :
$50 *
At a glance
- Originator AVEO Pharmaceuticals; Merck & Co
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 10 Aug 2007 AVEON Pharmaceuticals has successfully completed its multi-year collaborative agreement with Merck & Co
- 03 Mar 2005 GenPath Pharmaceuticals is now called AVEO Pharmaceuticals
- 17 Nov 2003 Preclinical trials in Cancer in USA (unspecified route)